A case of Frégoli syndrome following 24-hour levodopa-carbidopa intestinal gel infusion in a patient with Parkinson’s disease undergoing STN-DBS

A case of Frégoli syndrome following 24-hour levodopa-carbidopa intestinal gel infusion in a patient with Parkinson’s disease undergoing STN-DBS

Saved in:

Bibliographic Details
Main Authors:	Shunsuke Ogata, Katsuo Kimura, Katsuya Abe, Yumeko Urago, Noriko Hayashi, Misako Kunii, Naohisa Ueda, Fumiaki Tanaka
Format:	Article
Language:	English
Published:	Elsevier 2025-01-01
Series:	Clinical Parkinsonism & Related Disorders
Subjects:	Parkinson’s disease Levodopa-carbidopa intestinal gel (LCIG) Psychosis Frégoli syndrome Continuous dopaminergic stimulation
Online Access:	http://www.sciencedirect.com/science/article/pii/S2590112525000684
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Complications associated with intestinal infusion therapies in patients with Parkinson’s disease: a single-center retrospective study and 15-year experience
by: Igor Straka, et al.
Published: (2025-05-01)

Levodopa-induced motor complications associated with benserazide and carbidopa in Parkinson’s disease: a disproportionality analysis of the FAERS database
by: Huaide Qiu, et al.
Published: (2025-03-01)

Analytical method for simultaneous quantification of levodopa and carbidopa in the injectable oleogel formulation by HPLC
by: Deepa D. Nakmode, et al.
Published: (2025-02-01)

Symptom improvement in a South Asian patient with Parkinson’s disease treated with immediate- and extended-release carbidopa–levodopa: a case report
by: Gail Reiner, et al.
Published: (2025-07-01)

A phase I study to evaluate the effect of high-dose carbidopa on levodopa pharmacokinetics
by: Akane Hayashi, et al.
Published: (2025-07-01)

Buried bumper syndrome in percutaneous endoscopic gastrostomy with a jejunal extension tube in patients undergoing levodopa–carbidopa intestinal gel treatment
by: Masatoshi Nakagawa, et al.
Published: (2023-12-01)

USE OF THREE-COMPONENT LEVODOPA (LEVODOPA/CARBIDOPA/ENTACAPONE) TO CORRECT NOCTURNAL SYMPTOMS OF PARKINSON,S DISEASE
by: T. K. Kulua, et al.
Published: (2015-08-01)

Fregoli Delusion: A Rare Subtype of Delusional Misidentification Syndromes (DMSs)
by: Farnaz Ghannadi, et al.
Published: (2025-02-01)

Hyponatremia in Parkinson’s Disease: The Impact of Carbidopa-Levodopa Therapy
by: Elizabeth Schumacher, et al.
Published: (2025-06-01)

Bioequivalence of Foslevodopa/Foscarbidopa continuous subcutaneous infusion to arm, thigh, or flank versus abdomen in healthy and advanced Parkinson’s disease individuals
by: Yi Rang Han, et al.
Published: (2025-01-01)

Continuous Dopaminergic Stimulation-Based Levodopa Treatment in Patients with Early to Mid-Stage Parkinson’s Disease: A Systematic Review and Meta-Analysis
by: Rong Tang, et al.
Published: (2025-05-01)

Target-Controlled Sedation with Propofol Infusion for PEG-J Placement in Advanced Parkinson’s Disease: A Prospective Observational Study on Safety and Feasibility
by: Janos Szederjesi, et al.
Published: (2025-03-01)

How to dose extended-release carbidopa-levodopa capsules (IPX203, CREXONT®) in patients with Parkinson’s disease
by: Robert A. Hauser, et al.
Published: (2025-01-01)

Discinesias induzidas por levodopa em 176 pacientes com doença de Parkinson Levodopa-induced dyskinesias in 176 parkisonian patients
by: Maria Sheila G. Rocha, et al.
Published: (1995-12-01)

Satisfaction and Preferences for Infusion Therapies in Advanced Parkinson’s Disease—Patient Perspective
by: Julia Węgrzynek-Gallina, et al.
Published: (2024-12-01)

Articulatory Changes in Vowel Production following STN DBS and Levodopa Intake in Parkinson’s Disease
by: Vincent Martel Sauvageau, et al.
Published: (2015-01-01)

Experience in using levodopa-benserazide
by: Elena Anatolyevna Katunina, et al.
Published: (2015-10-01)

Attempted Suicide in a Parkinsonian Patient Treated with DBS of the VIM and High Dose Carbidopa-Levodopa
by: Ayotunde Ayobello, et al.
Published: (2019-01-01)

Levodopa / opicapone as a complement to STN-DBS in clinical practice. A retrospective single-centre analysis.
by: Moritz A. Loeffler, et al.
Published: (2024-12-01)

Prosody and levodopa in Parkinsons disease
by: Luciana Lemos de Azevedo, et al.
Published: (2013-11-01)

Contribution of dopaminergic polymorphisms to levodopa treatment response and drug concentration in Chinese patients with Parkinson’s disease
by: Xiaoqin He, et al.
Published: (2025-01-01)

Low serum uric acid levels and levodopa-induced dyskinesia in Parkinson's disease
by: Nayron Medeiros Soares, et al.
Published: (2023-01-01)

Diagnostic prediction model for levodopa-induced dyskinesia in Parkinson’s disease
by: Bruno Lopes SANTOS-LOBATO, et al.
Published: (2020-04-01)

Evaluation of the potential therapeutic effect of africanized honeybee venom (Apis mellifera Linnaeus) on levodopa-induced dyskinesias in mice
by: CAMILA G. DANTAS, et al.
Published: (2025-06-01)

Effect of levodopa on interleukin-15 and RANTES circulating levels in patients affected by Parkinson's disease
by: Sebastiano Gangemi, et al.
Published: (2003-01-01)

Harbinger of storm: influence of Oliver Sacks on levodopa therapy in early 1970s
by: Bruno Lopes dos Santos-Lobato, et al.
Published: (2016-08-01)

Efficacy and safety of levodopa in secondary dystonia due to neurological Wilson disease (LIDWID)
by: Jayantee Kalita, et al.
Published: (2025-01-01)

Working memory in Parkinson's disease patients: clinical features and response to levodopa Memória de trabalho em pacientes com doença de Parkinson: características clínicas e resposta a levodopa
by: Rogério Beato, et al.
Published: (2008-06-01)

The Influence of pH on the Catalytic Capacity of Levodopa in the Electroreduction Processes of Zn<sup>2+</sup> Ions
by: Jolanta Nieszporek, et al.
Published: (2025-06-01)

Efficacy and motor complications of original and generic levodopa in Parkinson&#39;s disease treatment
by: Kasemsap N, et al.
Published: (2016-05-01)

Development and study of mucoadhesive microcapsules for the nasal levodopa delivery
by: D. S. Gordeeva, et al.
Published: (2024-11-01)

Quality of life scale in parkinson's disease PDQ-39 - (Brazilian Portuguese version) to assess patients with and without levodopa motor fluctuation Escala para qualidade de vida na doença de Parkinson - PDQ 39 (versão do Português falado no Brasil) como instrumento para avaliação de pacientes com e sem flutuação motora decorrente da levodopa
by: Renata Guzzo Souza, et al.
Published: (2007-09-01)

Translational profiling reveals novel gene expression changes in the direct and indirect pathways in a mouse model of levodopa induced dyskinesia
by: Sabika Jafri, et al.
Published: (2025-03-01)

Deciphering the effects of STN DBS on neuropsychiatric fluctuations in Parkinson’s disease
by: Mari Muldmaa, et al.
Published: (2024-10-01)

Executive dysfunctions impair and levodopa improves articulatory timing in Parkinson‘s disease
by: Elisa Herbig, et al.
Published: (2025-07-01)

Levodopa induces thyroid function regulation in a patient with thyroid hormone resistance and Parkinson’s disease: a case report
by: Gabriela Rozo-Paz, et al.
Published: (2025-03-01)

Improving treatment for Parkinson's disease: Harnessing photothermal and phagocytosis-driven delivery of levodopa nanocarriers across the blood-brain barrier
by: Kaili Liang, et al.
Published: (2024-12-01)

Inefficacy of Repetitive Transcranial Magnetic Stimulation in Parkinson’s Disease Patients with Levodopa-Induced Dyskinesias: Results from a Pilot Study
by: Alma Medrano-Hernández, et al.
Published: (2025-07-01)

Image-guided optimization of current steering in STN-DBS for Parkinson's disease
by: Atsushi Umemura, et al.
Published: (2025-07-01)

Levodopa–carbidopa intestinal gel for multiple system atrophy with motor fluctuations: a case series
by: Tatou Iseki, et al.
Published: (2025-08-01)